Furthermore, recent work indicates that PD033299, which selectively inhibits CDK6, might be efficacious against multiple myeloma (Huang et al., 2012) and MLL-rearranged AML (Placke et al., 2014), malignancies where the pre-leukemic cell of origin is thought to be an HSC. Here, KMT2A is linked to plasma cell myeloma.